BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

Ki vehet részt

• Informed Consent: Signed informed consent by the participant or legally authorized representative
• Age \& Performance Status:; Age ≥ 18 years; ECOG performance status ≤ 2
• Diagnosis \& Disease Criteria:; Histologically confirmed B-NHL, including LBCL, MCL, and FL/MZL subtypes meeting specified prior treatment conditions; BAFF-R expression on lymphoma cells required
• Measurable Disease: Tumor ≥1.5 cm on CT/PET scan or evidence of disease in blood, BM, GI, skin, or spleen
• Prior CAR T-cell Therapy: Allowed if ≥ 3 months since last treatment and CD19 CAR-T persistence < 5% before leukapheresis
• Organ Function \& Laboratory Criteria:; Hematologic: ANC ≥ 1000/μL, Platelets ≥ 75,000/μL (exceptions for BM involvement); Liver Function: Bilirubin ≤ 1.5x ULN (except Gilbert's), AST/ALT < 3x ULN; Renal Function: CrCl ≥ 50 mL/min; Cardiac \& Pulmonary: LVEF ≥ 45%, QTcF ≤ 480 ms, O₂ saturation > 91% on room air
• Infectious Disease Screening: Seronegative for HIV, active HBV, active HCV (or undetectable viral load if positive)
• Reproductive Considerations:; Negative pregnancy test for females of childbearing potential; Use of effective contraception or abstinence through 3 months post-treatment

Ki nem vehet részt

• Prior Therapies \& Transplants:; Prior allogeneic SCT; Autologous SCT < 6 months before leukapheresis; Concurrent systemic steroids or chronic immunosuppressant use
• Disease-Specific Exclusions:; Cardiac lymphoma involvement; Need for urgent therapy due to tumor-related complications (e.g., bowel obstruction)
• Medical Conditions:; Active autoimmune disease requiring immunosuppressants; Primary immunodeficiency; Cardiac conditions, including NYHA Class III/IV heart disease, arrhythmia, recent MI (≤ 6 months), stroke (≤ 6 months), or significant VTE (≤ 6 months); Neurologic conditions, including prior optic neuritis, CNS inflammatory diseases, or seizure disorders; History of malignancy, unless resected/treated with curative intent or in remission for ≥ 3 years; Uncontrolled systemic infections or active CNS lymphoma
• Pregnancy \& Breastfeeding: Females who are pregnant or nursing
• Other Considerations:; Investigator-determined safety concerns; Potential noncompliance with study procedures